Memantine Hydrochloride Capsule, Extended Release
Product Images NDC 33342-221

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 33342-221). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantine-er-tab-14-mg-100-blister-carton.jpg (Memantine Er Tab 14 mg 100 Blister Carton)

FDA Label Image

125 (Memantine Er Tab 14 mg 30s)

125 (Memantine Er Tab 14 mg 30s)
Each extended-release capsule contains T Memanine hydrochioride USP 14 mg. The usual dosage can be found in the package insert for once-daily use. Store Memantine at 20° to 25°C (68°F to 77°F) and keep it in a tightly closed container as described in the USP. This medication should be kept out of reach of children. The brand responsible for this product is Macicoids PharmaUSA, Inc. and it comes in a package of 30 capsules.*
FDA Label Image

Memantine-er-tab-21-mg-100-blister-carton.jpg (Memantine Er Tab 21 mg 100 Blister Carton)

Memantine-er-tab-21-mg-100-blister-carton.jpg (Memantine Er Tab 21 mg 100 Blister Carton)
This product is a package of Memantine Hydrochloride Extended Release Capsules with a dosage of 10mg. The capsules are designed for once daily use. Each box contains 100 capsules.*
FDA Label Image

125 (Memantine Er Tab 21 mg 30s)

125 (Memantine Er Tab 21 mg 30s)
Each extended-release capsule contains Memantine hydrochloride USP 21 mg. The usual dosage can be found in the package insert along with full prescribing information. This medication should be stored in a closed container at temperatures between 15 to 30 degrees Celsius (58 to 86 degrees Fahrenheit). The capsules are to be kept out of reach of children. This pharmaceutical product is from Macleods Pharma USA, Inc.*
FDA Label Image

Memantine-er-tab-28-mg-100-blister-carton.jpg (Memantine Er Tab 28 mg 100 Blister Carton)

Memantine-er-tab-28-mg-100-blister-carton.jpg (Memantine Er Tab 28 mg 100 Blister Carton)
This is a product description for Memantine Hydrochloride Extended Release Capsules. The medication is available in a 28 mg strength and comes in a pack of 100 capsules (10 x 10 unit doses) for once daily use. The packaging also includes the NDC number 33342-222-12. The text might contain additional information or instructions regarding the usage and storage of the medication.*
FDA Label Image

125 (Memantine Er Tab 28 mg 30s)

125 (Memantine Er Tab 28 mg 30s)
This text provides information on an extended-release capsule containing 28 mg of Memantine Hydrochloride USP. It also mentions the usual dosage instructions, storage conditions, and details about the manufacturer. Additionally, it includes a caution to keep the drug out of reach of children and provides contact details for the manufacturer.*
FDA Label Image

Memantine-er-tab-7-mg-100-blister-carton.jpg (Memantine Er Tab 7 mg 100 Blister Carton)

FDA Label Image

125 (Memantine Er Tab 7 mg 30s)

125 (Memantine Er Tab 7 mg 30s)
This is a product label for Memantine Hydrochloride Extended-Release Capsules, each capsule containing 7mg of Memantine hydrochloride USP. The usual dosage and storage instructions are provided, including recommended temperature ranges for storage. The manufacturer is listed as Macleods Pharma USA, Inc. Keep this medication and all drugs out of the reach of children.*
FDA Label Image

Memantine-er-tab-figure-1.jpg (Memantine Er Tab Figure 1)

Memantine-er-tab-figure-1.jpg (Memantine Er Tab Figure 1)
Mean (+ SEM) Change from Baseline in SIB Score from a study comparing the effects of Memantine HCI ER 28 mg/AChEI to Placebo/AChEI over 12 weeks of treatment. The graph shows data points at 16, 20, and 24 weeks, illustrating the clinical decline.*
FDA Label Image

Memantine-er-tab-figure-2.jpg (Memantine Er Tab Figure 2)

Memantine-er-tab-figure-2.jpg (Memantine Er Tab Figure 2)
This text appears to show a graph or chart representing the cumulative percentage of patients at different levels. It includes data for Memantine HCI ER 28 mg/AChEI and Placebo/AChEI. The graph might be related to changes in SIB (Severe Impairment Battery) scores from baseline.*
FDA Label Image

Memantine-er-tab-figure-3.jpg (Memantine Er Tab Figure 3)

Memantine-er-tab-figure-3.jpg (Memantine Er Tab Figure 3)
The text is not-readable.*
FDA Label Image

Memantine-er-tab-figure-4.jpg (Memantine Er Tab Figure 4)

Memantine-er-tab-figure-4.jpg (Memantine Er Tab Figure 4)
This is a chart showing the percentage of patients experiencing different levels of improvement or worsening while taking Memantine HCI ER 28 mg/AChEI compared to Placebo/AChEI in a study. The levels of improvement are categorized as Marked, Moderate, and Minimal Improvement, as well as No Change. Similarly, levels of worsening are categorized as Minimal, Moderate, and Marked Worsening based on CIBIC Plus ratings.*
FDA Label Image

145 (Memantine Er Tab Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.